{"name":"NeoGenomics","slug":"neogenomics","ticker":"NEO","exchange":"NASDAQ","domain":"neogenomics.com","description":"NeoGenomics Laboratories, Inc., also known as NeoGenomics or Neo, is an American CLIA-certified clinical laboratory, pharma services and information services company that specializes in cancer genetics diagnostic testing. The company's testing services include cytogenetics, fluorescence in situ hybridization (FISH), flow cytometry, immunohistochemistry, anatomic pathology, and molecular genetics.","hq":"Fort Myers, FL","founded":0,"employees":"2500","ceo":"Chris Smith","sector":"Cancer Diagnostics / Genomic Testing","stockPrice":8.34,"stockChange":0.28,"stockChangePercent":3.47,"marketCap":"$1.1B","metrics":{"revenue":660000000,"revenueGrowth":10.6,"grossMargin":43.2,"rdSpend":37077000,"netIncome":-108025000,"cash":159618000,"dividendYield":0,"peRatio":26.1,"fiscalYear":"FY2015"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"NeoGenomics Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"NeoGenomics reported revenue of $253.4 million for the fourth quarter and $1.02 billion for the full year 2023.","drugName":"","sentiment":"neutral"},{"date":"2023-11-15","type":"deal","headline":"NeoGenomics and Invitae Announce Strategic Partnership to Enhance Cancer Diagnostic Capabilities","summary":"NeoGenomics and Invitae announced a strategic partnership to enhance cancer diagnostic capabilities.","drugName":"","sentiment":"positive"},{"date":"2023-08-01","type":"regulatory","headline":"NeoGenomics Receives FDA Clearance for its Next-Generation Sequencing (NGS) Test for Solid Tumors","summary":"NeoGenomics received FDA clearance for its NGS test for solid tumors.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxNbGdRaW9CWGlINjNNUnB1MG5mc2hsQ0ZPVmVWUTdVWHFVbUJfWFF6RWpiZFcxOHVHY29aN0hpc2l5MDJOQUZDT243eU9YWDN4azRqd25OVEF6S1piazVXcUVHV0UyOTJscGhFZnlOcVZFYzRrN2JncmFWM1kzMVMyZDh2cHU4RjlFamFjckZ3Xy1UM3E2UENzSnNEVkppZWZnd09xWEZlTmQyWGFKTTM3anVIME9CcWtyWW9pUVJEV3hJdVk?oc=5","date":"2026-04-03","type":"pipeline","source":"AD HOC NEWS","summary":"NeoGenomics Inc Stock: Precision Oncology Leader Faces Growth Challenges in Competitive Diagnostics - AD HOC NEWS","headline":"NeoGenomics Inc Stock: Precision Oncology Leader Faces Growth Challenges in Competitive Diagnostics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxPRTRGWlpUM1VyQXVGZjhJb1VWSjIxb3Y5bmtib1VmdkFxM2JFU3h3RXZJUElHZUF0TGxnOHVsSW9BUkJmUEFRV2ZZSFJ1YWNramVoeC1OTnh3TFd3eTZfUzJKUFY4U0RVTVk5TGRSNk9udXZxY0lGTS15cFhZSzdTOE5BZ2NJSTgwTHVyYjIxZUxfRGhTYTRkY0FRRHlmWnpEZ0htYVRycTZZUEY0YzYtV00xTmdHaUp3NmZURE9SNUg?oc=5","date":"2026-04-03","type":"pipeline","source":"AD HOC NEWS","summary":"NeoGenomics Inc stock: Precision oncology leader facing growth hurdles - AD HOC NEWS","headline":"NeoGenomics Inc stock: Precision oncology leader facing growth hurdles","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiywFBVV95cUxONlVEWEw2Y3RqM1prYU40dUVKbjVJWU8wWklVYmVaNXAzTnVvN2dDdFFYR2VfTEJBQVZDTWlzZmthYjVua3dvZHVQNm45aVE4VG9IMl83Ni14WktSQUppU3RDaFNWbTE2WGRic0Q0eTNKSnBBaENURW1jcnZEcVM1MmE1emtYNzdsVFdOM3JTazhZNDJDRDhndXl2WG1McjROejR0VGFNc0RHWU5KSU5vY1MtOEdERWtpelYyWTFiZXBPVEhwTWdnb1VqUdIB0AFBVV95cUxNcWs2blM2Nkc2X1hzYXZ3bk1ad3VmUGdXUDBGUUdIaTRjSUplZlpZQzJNR1dSLUxyZEpDZFkwTExqa1ltZlNTWGFvX3lTSmFIM2cwLUdPVlUxblF0SGtZa1BLLUZHNWF3YXVMZ183MEVjX19EQVRMMWdTbXZaOThQZlJOUHlndVV0U3c3Q2RqMkZjZ2NGaVZ1WVp2b010MjVDS2lVdmRjYmw4Zjh4VGRvTERJM2RqRnRSci1YSGNnMHV0WUJDdlJpR0U0d29HV3R3?oc=5","date":"2026-03-17","type":"pipeline","source":"simplywall.st","summary":"Assessing NeoGenomics (NEO) Valuation After Recent Share Price Weakness - simplywall.st","headline":"Assessing NeoGenomics (NEO) Valuation After Recent Share Price Weakness","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxPNmY0SUFQVVlUU3o1bVNrbVctVGhWdDFmRUlyOHVvNld3Y3lCU3RqZnBiWFhhRkFIc3Z6WjM4V1lLN3Z5Z1Y5UnVYMjBKc0lnLVRNc0RDSTItcTBjMUlZamNfVmIwY1NlZ05MampwdzByTmdiRWtaQ2NCQ0RNb1ZWMzdRZzU3MU5HSS1KOFJ0aXNTYm9ud3FUdmlodE9DZw?oc=5","date":"2026-03-16","type":"pipeline","source":"Yahoo Finance","summary":"NeoGenomics, Natera, and Amphastar Pharmaceuticals Shares Skyrocket, What You Need To Know - Yahoo Finance","headline":"NeoGenomics, Natera, and Amphastar Pharmaceuticals Shares Skyrocket, What You Need To Know","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxNSnlLV2ZIbVVnUFFLWFlCYnVBU0VLeldscjRHeEE0a3N6TXozSU1uaWVUUlFWV3BVcWJOZV95NExPRU5id0JCeU9EemRHQ0pPYVpJNGUzczBQQWdvNUVVbUx0UTVWcWZXVDAxZjFpcko1RkhucmVtQ29Uald4eTVDbnVmVDZYZG8tTEpEa1BMZkF0U2FmeFdmMzR4S1VaT1dFclJRU0hHTmtrMnl4QjZVczNaWWNkWml3aHlsT09NSkJTaE00?oc=5","date":"2026-02-17","type":"earnings","source":"Investing.com","summary":"NeoGenomics Q4 2025 slides: 11% revenue growth, RaDaR ST launch imminent - Investing.com","headline":"NeoGenomics Q4 2025 slides: 11% revenue growth, RaDaR ST launch imminent","sentiment":"neutral"},{"date":"2026-02-17","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-02-17","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxQeHlrNTVjU0d0Vm9rQzdrbmdwMEhZazhEZ1FpclgtamlPa0szRHZLTkN5bmpSN2dHV2lmcDRZSmNsUWg4SDc2c1lVS0txam5xWVpnd1Z1dFRsaW52U3RXem9CNklrVFhVVHl4M3l3Sm9JRWhoZG5sTEhUTXJlUlFDaXp3dENaekJtTjFWVUR2NXBDMzl0aHFJ?oc=5","date":"2026-01-25","type":"pipeline","source":"Seeking Alpha","summary":"NeoGenomics: Distribution Moat In Community Oncology (NASDAQ:NEO) - Seeking Alpha","headline":"NeoGenomics: Distribution Moat In Community Oncology (NASDAQ:NEO)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxORWhnSnpnZTBLdkZSeVlSMTFSTmlkem5qa2gycXhiM0EwMXlKenpjV0p0Z2xZckpXSU85d251MFJIdXNyT3A3d1dtUkE2TUpUbkFaLXFhVWFoUFlTVmlEdjFKSDhYb3FMdzBfMURJN19EN21vc3pLRmc4SFdoQjBtUXFNVkQwdmJ4SlBvSEt0emxxMHFVU3hlcnF6d21MZTRXRGlOdjQ5cEV6S2hlanUweTRZQ0FQYURVZDRvSXBPQQ?oc=5","date":"2026-01-05","type":"pipeline","source":"Stock Titan","summary":"Cancer diagnostics firm NeoGenomics joins major J.P. Morgan event - Stock Titan","headline":"Cancer diagnostics firm NeoGenomics joins major J.P. Morgan event","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxQMV84R0JUbnZuemJrZ0R3aUJfamhfcjlPVGtObERwMF9pQVJPaHh4eUtlbENCMnhyd3YtYm5JVHZEYnE0RHNGaGI1UUY0b3B3enNxUlUyLUhFejhRaERfdUM2cWxSOHNUTFE4Z3hLMDB3WHpEX3lzVmNNbG1Ba0RnbHpCVnhmLUg4Ri1XbG5TcThBUQ?oc=5","date":"2025-10-30","type":"earnings","source":"Yahoo Finance","summary":"NeoGenomics (NEO): Losses Widen, Profitability Still Elusive as Revenue Trails Market Growth - Yahoo Finance","headline":"NeoGenomics (NEO): Losses Widen, Profitability Still Elusive as Revenue Trails Market Growth","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5gFBVV95cUxQOUliRlhXaTMxVFZGZUwwRUI5LUJOc29UNnRCZjFSRC1ia1g4QWFpUlBmTUpNTU1FS2hlZlFXLXVnR3d5eVFYdmw1OTg0bS1keGc2V3hQMW5Ib2JhYzdyNTJnVzJVWkxzSjFQWnFhVVlueGZhYlhxWlBHV25naXRsdVNoWjJGMk9pUHV0dlNmSDBKNV9GcXhqVGJQQnZnSWhUSXNaQjNMVGNtQ2F2WnNWdXRtSVlTaHlDTGdhY1lQc3FsSk5TakpnQllLRkYxeXkxcHdvTkZGaW9jOWNTM09oM1h0RUZWdw?oc=5","date":"2025-10-29","type":"earnings","source":"FinancialContent","summary":"NEO Q3 Deep Dive: Clinical Volume Gains and New Product Launches Shape Outlook - FinancialContent","headline":"NEO Q3 Deep Dive: Clinical Volume Gains and New Product Launches Shape Outlook","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxPTG05aUhhOHBmT212ODdFVkJrMWFicGZxYWE2VTFyNUVHaG1TWWhnUE82cXJfZ3cyLWhNWWo2bnpscU9aNFB4bkV0YmVhRGQyWTVUclNYczdwMDU5X0dvQmd6SWd4VHBkb0VqVVcySkdDOWFjNDFWOEFuSHFGLVR4TzczN25RTVMxbWRSVzkxMlF2Q2RULXc?oc=5","date":"2025-10-27","type":"pipeline","source":"Yahoo Finance","summary":"How Investors Are Reacting To NeoGenomics (NEO) Showcasing RaDaR ST Test for Oncology Drug Development - Yahoo Finance","headline":"How Investors Are Reacting To NeoGenomics (NEO) Showcasing RaDaR ST Test for Oncology Drug Development","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2gFBVV95cUxPTkVpSDA4dTBJa3NVOVVhcXFsbFItaFFzMk8wNXItRG50ZHpFZzRVd3FESmdVZHlIRVVlclJ0cnVnRXhZNzctVlR0U0dQZExZUGJPY0M2LXNOM3Q0clpQMllWRmx6cDdqaVM5ZFNiVlFBNlE5XzVkNVRfazRmN1hacDNGTlZ1ZEx3SlNJWTM5dkUtT1FOQmFvMzVLWUpLMFliRzZRUXlTdzJhNFRJYTFnRzlhU0FtTHBiZGlrbklfQVJRZE4tRmUxWnFWRFNmT0NfX3pVUHV5SHFzdw?oc=5","date":"2025-07-30","type":"earnings","source":"The News-Press","summary":"Fort Myers-based NeoGenomics sees stock plunge after reporting mixed results for Q2 - The News-Press","headline":"Fort Myers-based NeoGenomics sees stock plunge after reporting mixed results for Q2 - The News","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxQQVpLOVp3NTR4Q2ZlSDd3WEZUYVFibkhoT0FzM1F3bW12N0s1YVdRQVc3MTBTYUhBLWVIYXJhNGt1TnFTWlVsWGFETU4yeVk2N1pVMHladi1OdXF6SElmSm5Zd2dXZW9rMXN6X2xzaDFtTzRPQWJrZXBIRFJ1MmhDTXc0UEtWSElUV1JiUmQ0T3h3dG5pMXRpX3AyODJCSlpRQ21oLQ?oc=5","date":"2025-04-07","type":"pipeline","source":"Business Wire","summary":"NeoGenomics Completes Acquisition of Pathline - Business Wire","headline":"NeoGenomics Completes Acquisition of Pathline","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Invitae","Foundation Medicine","Caris Life Sciences"],"therapeuticFocus":["Cancer Diagnostics","Genomic Testing"],"financials":{"source":"sec_edgar+yahoo","revenue":5000000,"revenuePeriod":"2015-12-31","revenueHistory":[{"value":5000000,"period":"2015-12-31"},{"value":5000000,"period":"2014-12-31"},{"value":5000000,"period":"2013-12-31"},{"value":5000000,"period":"2012-12-31"}],"grossProfit":314293000,"grossProfitHistory":[],"rdSpend":37077000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-108025000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":159618000,"cashHistory":[],"totalAssets":1359830000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":2500,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":8.34,"previousClose":8.06,"fiftyTwoWeekHigh":13.74,"fiftyTwoWeekLow":4.72,"fiftyTwoWeekRange":"4.72 - 13.74","fiftyDayAverage":9.76,"twoHundredDayAverage":9.31,"beta":1.71,"enterpriseValue":1296124416,"forwardPE":26.1,"priceToBook":1.29,"priceToSales":1.49,"enterpriseToRevenue":1.78,"enterpriseToEbitda":-711.76,"pegRatio":0,"ebitda":-1821000,"ebitdaMargin":-0.2,"freeCashflow":17203250,"operatingCashflow":5230000,"totalDebt":409456000,"debtToEquity":48.9,"currentRatio":4.26,"returnOnAssets":-2.9,"returnOnEquity":-12.4,"analystRating":"2.2 - Buy","recommendationKey":"buy","numberOfAnalysts":8,"targetMeanPrice":14.81,"targetHighPrice":17,"targetLowPrice":13,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":1.5,"institutionHeldPercent":102.8,"sharesOutstanding":130143833,"floatShares":119196168,"sharesShort":8371684,"shortRatio":4.21,"shortPercentOfFloat":6.5,"epsTrailing":-0.84,"epsForward":0.32,"revenuePerShare":5.68,"bookValue":6.49,"officers":[{"age":64,"name":"Mr. Anthony P. Zook","title":"CEO & Director"},{"age":52,"name":"Mr. Warren  Stone","title":"President & COO"},{"age":49,"name":"Ms. Elizabeth A. Floegel","title":"Chief Digital & Information Officer"},{"age":41,"name":"Ms. Alicia C. Olivo","title":"Executive VP of Business Development, General Counsel & Corporate Secretary"},{"age":48,"name":"Mr. Abhishek  Jain","title":"Executive VP & CFO"},{"age":56,"name":"Mr. Gregory D. Aunan","title":"Senior VP & Chief Accounting Officer"},{"age":null,"name":"Ms. Kendra  Sweeney","title":"Vice President of Investor Relations & Communications"},{"age":null,"name":"Mr. Clarence  Cooper Esq.","title":"Vice President of Compliance & Privacy"}],"industry":"Diagnostics & Research","irWebsite":"","website":"https://www.neogenomics.com","phone":"239 768 0600"}}